GlassScriptPhysician profile
Christopher D Biehl
NPI 1407218530
$1,596.83
in general payments reported to CMS, 2019-2025
14 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $12.08 · 2023: $266 · 2024: $469 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.62 | 2021-2025 | |
| Pfizer INC. | $385.63 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $149.42 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $146.27 | 2021 | |
| Zimvie INC. | $144.41 | 2024 | |
| Nevro Corp. | $115.77 | 2024 | Senza |
| Ibsa Pharma INC. | $66.02 | 2021-2025 | Tirosint, Tirosint, Licart |
| Biodelivery Sciences International, INC. | $42.26 | 2021 | |
| Collegium Pharmaceutical, INC. | $40.53 | 2021-2025 | Belbuca |
| Valinor Pharma, LLC | $40.19 | 2025 | Movantik |
| Boston Scientific Corporation | $17.20 | 2023 | Wavewriter Alpha Prime 16 |
| Indivior INC. | $13.43 | 2023 | Sublocade |
| Azurity Pharmaceuticals, INC. | $13.00 | 2023 | Horizant |
| Redhill Biopharma INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Biehl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.